Literature DB >> 2220642

Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation.

L Rudas1, P W Pflugfelder, F N McKenzie, A H Menkis, R J Novick, W J Kostuk.   

Abstract

To determine the prevalence, time course and factors responsible for hyperlipidemia after heart transplantation, 83 consecutive 1-year survivors were studied. By 1 year, 83% of patients had serum total cholesterol levels greater than 5.2 mmol/liter (200 mg/dl) and 28% of the patients had serum total cholesterol higher than the age- and sex-matched ninety-fifth percentile. At the end of 1-year follow-up, serum total cholesterol correlated with the recipient age (p less than 0.0001), the preoperative cholesterol level (p less than 0.001), the actual dose of maintenance prednisone at 1 year (p less than 0.02) and the cumulative 1-year steroid dose (p less than 0.03). Similarly, the serum triglyceride level at 1 year correlated with the pretransplant level of serum triglycerides (p less than 0.0001), recipient age (p less than 0.03) and cumulative 1-year steroid dose (p less than 0.03). Patients with a pretransplant diagnosis of coronary artery disease had a significantly higher level of serum total cholesterol and triglyceride levels at 1 year (p less than 0.02 and p less than 0.03, respectively). Heart transplant recipients with body mass index greater than or equal to 25 kg/m2 also presented with significantly elevated serum total cholesterol and triglyceride levels at 1 year compared with nonobese patients (p less than 0.01 and p less than 0.002, respectively). Hyperlipidemia occurs frequently and is detected within the first month after heart transplantation. Optimal management of this problem requires further study.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2220642     DOI: 10.1016/0002-9149(90)90518-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.

Authors:  J C Adkins; D Faulds
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

Review 2.  Primary care of the renal transplant patient.

Authors:  J D Pirsch; R Friedman
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

Review 3.  Acute and chronic phagocyte determinants of cardiac allograft vasculopathy.

Authors:  Kristofor Glinton; Matthew DeBerge; Xin-Yi Yeap; Jenny Zhang; Joseph Forbess; Xunrong Luo; Edward B Thorp
Journal:  Semin Immunopathol       Date:  2018-08-23       Impact factor: 9.623

4.  Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate.

Authors:  M deLorgeril; P Boissonnat; C A Bizollon; J Guidollet; G Faucon; J P Guichard; R Levy-Prades-Sauron; S Renaud; G Dureau
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.

Authors:  Gillian M Keating; Douglas Ormrod
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Prominence of coronary arterial wall lipids in human heart allografts. Implications for pathogenesis of allograft arteriopathy.

Authors:  B M McManus; K J Horley; J E Wilson; G T Malcom; T J Kendall; R R Miles; G L Winters; M R Costanzo; L L Miller; S J Radio
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

Review 7.  Steroid-free and steroid withdrawal protocols in heart transplantation: the review of literature.

Authors:  Massimo Baraldo; Giorgia Gregoraci; Ugolino Livi
Journal:  Transpl Int       Date:  2014-04-12       Impact factor: 3.782

8.  Low-Density Lipoprotein Cholesterol Level Trends and the Development of Cardiac Allograft Vasculopathy After Heart Transplantation.

Authors:  Natasha Aleksova; Fraz Umar; Jordan Bernick; Lisa M Mielniczuk; Heather J Ross; Sharon Chih
Journal:  CJC Open       Date:  2021-07-16

9.  Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.

Authors:  Rabea Asleh; Alexandros Briasoulis; Naveen L Pereira; Barry A Boilson; Brooks S Edwards; Rosalyn Adigun; Simon Maltais; Richard C Daly; Amir Lerman; Sudhir S Kushwaha
Journal:  ESC Heart Fail       Date:  2018-07-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.